Plate Nº 46 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Some High-Fat Diets Boosted Immunotherapy in Mice, McGill Study Finds
McGill researchers found that of 12 diets tested in mice, several linked to weight gain improved responses to immune checkpoint inhibitors, pointing to a food-microbe mechanism behind the so-called obesity paradox in cancer care.
By Priya Raman3 min read550 words
In brief
- The study tested 12 diets in mice and was published in Nature in 2026.
- Daniela Quail of McGill co-led the research with Logan Walsh, Bertrand Routy, and Arielle Elkrief.
- Several diets associated with obesity improved responses to immune checkpoint inhibitors, even after short feeding periods.
- Authors warn against adopting weight-gain diets, which carry well-documented health risks.
- The paper's DOI is 10.1038/s41586-026-10750-x.
Across 12 diets tested in mice, several patterns typically linked to weight gain improved responses to immune checkpoint inhibitors, a common form of cancer immunotherapy, a McGill University team reported in Nature. The finding complicates the usual advice to simply "eat healthy and exercise."
What did the study find?
Researchers fed mice 12 different diets and measured how the animals responded to immune checkpoint inhibitors, drugs that remove the brakes on the immune system so it can attack tumors. Several diets associated with obesity produced stronger anti-tumor responses than control diets, even after relatively short feeding periods. The advantage tracked with shifts in the gut microbiome, the trillions of microbes that live in the digestive tract.
"There is a synergistic relationship between the bacteria that reside in our GI tract and the food we eat," said Daniela Quail, associate professor in McGill's Department of Physiology and principal investigator at the Rosalind & Morris Goodman Cancer Institute.
Why is this called a paradox?
The work was inspired by a puzzling pattern known as the "obesity paradox" in cancer care. Although obesity raises the risk of developing cancer and shortens survival, several earlier studies found that cancer patients with a higher body mass index (BMI) sometimes respond better to immune checkpoint inhibitors than leaner patients.
The mouse data point away from body fat itself and toward what patients eat.
"Even with the right composition of bacteria in your gut, the foods you eat to nourish those populations can determine whether you respond to treatment," Quail said.
Quail co-led the study with Logan Walsh at McGill and Bertrand Routy and Arielle Elkrief at CR-CHUM, the University of Montreal hospital research center.
Should cancer patients eat differently?
Not on this evidence. The authors stress that the work is preclinical, meaning it was performed in mice, and that diets associated with weight gain carry well-documented risks for heart disease, diabetes, and other conditions.
"Our findings were surprising because they highlighted a benefit of some obesogenic diets," Quail said. "That tells us the relationship between diet and cancer treatment is more complex than a simple message to eat healthy and exercise."
The team's next step is to identify the specific dietary and microbial signals behind the effect, then test whether those signals can be delivered without the drawbacks of obesity.
How do checkpoint inhibitors work?
Immune checkpoint inhibitors block proteins such as PD-1 or CTLA-4, which tumors exploit to dampen T-cell activity. Once released from those brakes, T cells can attack cancer more aggressively. The drugs have transformed care for melanoma, lung cancer, kidney cancer, and several other malignancies, yet only a minority of patients respond. Researchers have spent years searching for ways to predict, or improve, who responds.
What are the study's limits?
Key caveats to keep in mind:
- The experiments used mouse cancer models, not human patients.
- Diet duration, exact composition, and mouse metabolism differ from human biology in important ways.
- The team has not yet pinpointed which molecules or bacterial species drive the improved responses.
- The findings cannot, on their own, justify any dietary change for people with cancer.
The full study, "Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy," appears in Nature and is available at DOI 10.1038/s41586-026-10750-x.
via Medical Xpress (Source)
More from Priya Raman
Show full bio
Senior reporter covering industry trends and analytics at SciBeat.
207 articles
Nearby plates
- Keto Diet Raises Small-Intestine Tumor Risk in MIT Mouse Study
- Sugar May Amplify the Gut Damage Antibiotics Cause
- When 'Healthy Fats' Undermine Cancer Immunity: Yale Study
- Microplastics Clog Liver Immune Cells and Drive Fat Buildup in Mice
- Identical Labels, Different Bodies: Processing Alone Changes Metabolism